<DOC>
	<DOC>NCT01925911</DOC>
	<brief_summary>To evaluate the effect of IPI-145 on the pharmacokinetics of midazolam, a cytochrome P450 3A (CYP3A) substrate; to assess the safety and tolerability of IPI-145 when administered with midazolam in healthy subjects.</brief_summary>
	<brief_title>Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam</brief_title>
	<detailed_description>- In Treatment Period 1, subjects will receive a single 2 mg oral dose of midazolam. - In Treatment Period 2, on Days 2-6, the same subjects will receive twice daily (BID) oral doses of 25 mg IPI-145; on Day 6, subjects will receive the morning dose of 25 mg IPI-145 concomitantly administered with 2 mg of midazolam.</detailed_description>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy men or women of nonchildbearing potential between 1850 years of age Body Mass Index (BMI): 18.0 32.0 kg/m2. In good health, determined by no clinically significant findings from clinical evaluations Provided written informed consent prior to any study specific procedures Women of childbearing potential Evidence of clinically significant medical conditions History of gastrointestinal disease or surgery that may affect drug absorption Positive or indeterminate tuberculosisspot test at screening Any active infection at the time of screening or admission Subjects with acute narrowangle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy subjects</keyword>
	<keyword>DDI</keyword>
	<keyword>CYP3A</keyword>
</DOC>